A new method of treatment for antibiotic-resistant bacteria and infectious disease has been discovered, according to a study published in the American Journal of Respiratory and Critical Care Medicine. It describes a new treatment pathway that benefits patients as well as healthcare providers.
Researchers from the University of Birmingham and Newcastle University discovered a rather unusual approach of removing antibodies from the bloodstream, which reduced the effects of chronic infections, days spent in the hospital, and the use of antibiotics.
In the study, two patients were identified with an infection that was resistant to antibiotics, a 64-year-old male, and a 69-year-old female. Both had a respiratory infection called bronchiectasis, which is associated with the bacterial organism, Pseudomonas aeruginosa.
Bronchiectasis is a disease that leads to permanent enlargement of the airways of the lungs. It is estimated that approximately 300,000 people in the UK are currently infected by the disease. Symptoms of this debilitating condition include a chronic cough, shortness of breath, coughing of blood, and chest pain. Bronchiectasis often affects patients beyond the age at which lung transplantation is possible
The bacterial organism in question, Pseudomonas aeruginosa, commonly occurs in patients suffering from bronchiectasis and is known to be a multi-drug resistant pathogen, having advanced antibiotic resistance mechanisms and it is generally associated with serious illness.
Participants in the study volunteered to be part of an explorative treatment that was built on previous findings from a research group for a cystic fibrosis study in 2014.
“These patients had an excess of a particular antibody in the bloodstream. In contrast to the protective effect normally associated with an antibody in these patients, the antibody stopped the immune system killing the Pseudomonas aeruginosin bacterium and this worsened the patients’ lung disease. Perhaps counter-intuitively, we decided to remove this antibody from the bloodstream and the outcomes were wholly positive,” explained Professor Ian Henderson.
Professor Henderson added: “This shows that we can improve patient wellbeing significantly, by reducing the need for treatment and the numbers of days spent in the hospital, which will also help to reduce the reliance on antibiotics. The next step is to do longer term studies to investigate whether an earlier intervention, with slightly less aggressive therapies, could help prevent disease progression in patients.”
Both patients in this study reported rapid improvement in health and well-being, greater independence, and improved mobility compared to any point in the previous two years. This also marks the first description of antibody-dependent enhancement of bacterial disease. The application of this particular method may be wide spreading to other bacterial infections and offers hope in the fight against antibiotic-resistant infections.